Evidence map›Paper›PMID 25511514›Full record

ReviewAnti-cancer agents in medicinal chemistry2015

Lessons from Nature: Sources and Strategies for Developing AMPK Activators for Cancer Chemotherapeutics.

Richard T Arkwright, Rahul Deshmukh, Nikhil Adapa, Ryan Stevens, Emily Zonder, Zhongyu Zhang, Pershang Farshi, Reda Saber Ibrahim Ahmed, Hossny Awad El-Banna, Tak-Hang Chan and 1 more

Open access · greenAbstract readReview
In one paragraph

Review in Anti-cancer agents in medicinal chemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Richard T Arkwright
Rahul Deshmukh
Nikhil Adapa
Ryan Stevens
Emily Zonder
Zhongyu Zhang
Pershang Farshi
Reda Saber Ibrahim Ahmed
Hossny Awad El-Banna
Tak-Hang Chan
Q Ping DouBarbara Ann Karmanos Cancer Institute and Department of Oncology, School of Medicine, Wayne State University, 540.1 HWCRC, 4100 John R Road, Detroit, MI 48201- 2013. doup@karmanos.org.
The Barbara Ann Karmanos Cancer Institute · US

Funding

Tumor Biology and Microenvironment (Program 1)P30CA022453 · NCI · WAYNE STATE UNIVERSITY · PI PAUL M STEMMER · 1985 to 2026
$68.4M
Roles of polymorphic COMT, tea polyphenols and proteasome in cancer preventionR01CA120009 · NCI · WAYNE STATE UNIVERSITY · PI DOU, QING PING · 2006 to 2010
$1.5M
The BCA2 Ubiquitin E3 Ligase as a Target in Breast CancerR01CA127258 · NCI · WAYNE STATE UNIVERSITY · PI DOU, QING PING · 2007 to 2011
$1.2M
(PQA1) Regulation of Metformin Response by Breast Cancer Associated Gene 2 (BCA2)R21CA184788 · NCI · WAYNE STATE UNIVERSITY · PI DOU, QING PING · 2014 to 2015
$364k
CIHRNCI NIH HHS 1R01CA20009NCI NIH HHS 5R01CA127258-05NCI NIH HHS P30 CA022453NCI NIH HHS P30 CA22453NCI NIH HHS R01 CA120009NCI NIH HHS R01 CA127258NCI NIH HHS R21 CA184788NCI NIH HHS R21CA184788
6 · The paper itself

Abstract

Adenosine Monophosphate-Activated Protein Kinase or AMPK is a highly-conserved master-regulator of numerous cellular processes, including: Maintaining cellular-energy homeostasis, modulation of cytoskeletaldynamics, directing cell growth-rates and influencing cell-death pathways. AMPK has recently emerged as a promising molecular target in cancer therapy. In fact, AMPK deficiencies have been shown to enhance cell growth and proliferation, which is consistent with enhancement of tumorigenesis by AMPK-loss. Conversely, activation of AMPK is associated with tumor growth suppression via inhibition of the Mammalian Target of Rapamycin Complex-1 (mTORC1) or the mTOR signal pathway. The scientific communities' recognition that AMPK-activating compounds possess an anti-neoplastic effect has contributed to a rush of discoveries and developments in AMPK-activating compounds as potential anticancer-drugs. One such example is the class of compounds known as Biguanides, which include Metformin and Phenformin. The current review will showcase natural compounds and their derivatives that activate the AMPK-complex and signaling pathway. In addition, the biology and history of AMPK-signaling and AMPK-activating compounds will be overviewed, their anticancer-roles and mechanisms-of-actions will be discussed, and potential strategies for the development of novel, selective AMPK-activators with enhanced efficacy and reduced toxicity will be proposed.

Indexed as

AMP-Activated Protein KinasesAnimalsAntineoplastic AgentsCell ProliferationEnzyme ActivatorsHumansNeoplasmsAMP-Activated Protein KinasesAntineoplastic AgentsEnzyme Activators

Identifiers

PMID25511514
PMCPMC5580392
OpenAlexW2167536742

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.